VistaGen Therapeutics (VTGN) Projected to Announce Quarterly Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to be issuing its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect VistaGen Therapeutics to announce earnings of ($0.3650) per share and revenue of $0.50 million for the quarter. Individuals may visit the the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Monday, June 15th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%. The firm had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.40 million. During the same period in the previous year, the firm earned ($1.67) EPS. On average, analysts expect VistaGen Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Up 4.5%

Shares of VistaGen Therapeutics stock opened at $0.24 on Thursday. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14. The company’s 50-day simple moving average is $0.45 and its 200-day simple moving average is $0.55. The firm has a market cap of $9.98 million, a price-to-earnings ratio of -0.13 and a beta of 0.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $0.95.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics during the 1st quarter worth $25,000. Marshall Wace LLP purchased a new position in shares of VistaGen Therapeutics in the 2nd quarter valued at about $69,000. Jane Street Group LLC acquired a new stake in shares of VistaGen Therapeutics in the second quarter valued at about $190,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of VistaGen Therapeutics by 56.9% in the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after purchasing an additional 24,655 shares during the period. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.